Home > Oncology > WCLC 2019 > Non-Small-Cell Lung Cancer > pTMB is a Feasible Predictive Biomarker for Chemoimmunotherapy

pTMB is a Feasible Predictive Biomarker for Chemoimmunotherapy

WCLC 2019

A biomarker which importance is clearly increasing, is the tumour mutational burden (TMB; number of somatic mutations per megabase [mut/Mb]). Furthermore, there has been some research into the role of plasma-based TMB as a biomarker, although this has been done only in anti-PD-L1 therapy studies or in combination therapy with PD-L1/cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade. Aggarwal et al. investigated whether pTMB can be used as a predictive biomarker in chemoimmunotherapy.

The researchers used a cohort which consisted of 66 treatment-naïve patients with stage IV non-squamous NSCLC without EGFR/ALK/ROS1/BRAF-mutations. Patients were randomised to pembrolizumab monotherapy (n=31) and pembrolizumab + chemotherapy (n=36). At 9 weeks, pTMB was compared to Response Evaluation Criteria in Solid Tumors (RECIST) response and 6 months durable clinical benefit. High and low pTMB were defined at a cut-off of 16 mut/Mb [1].

The results show...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on